Omalizumab (Xolair®)

Assessment Status Rapid Review Complete
Drug Omalizumab
Brand Xolair®
Indication As an add-on therapy for the treatment of chronic spontaneous urticaria (CSU) in adult and adolescent (12 years and above) patients with inadequate response to H1-antihistamine treatment. 
Assessment Process
Rapid review commissioned 25/03/2014
Rapid review completed 25/04/2014
Rapid review outcome Full Pharmacoeconomic Assessment Not Recommended